Table 2 The association between BRD7, YB1 expression and clinicopathologic features of breast cancer
Variables | YB1 expression | BRD7/YB1 expression | ||||
|---|---|---|---|---|---|---|
Features | YB1H | YB1L | P | BRD7LYB1H | BRD7HYB1L | P |
Age (Y) | ||||||
 <46 | 50 (45.5) | 56 (50.9) | 0.418 | 35 (49.3) | 32(45.1) | 0.737 |
 ≥46 | 60 (54.5) | 54 (49.1) | 36 (50.7) | 39(54.9) | ||
Tumor size (%) | ||||||
 T1~2 | 50 (45.5) | 71 (64.5) | 0.008** | 31 (43.7) | 46 (64.8) | 0.020* |
 T3~4 | 60 (54.5) | 39 (35.5) | 40 (56.3) | 25 (35.2) | ||
Nodal metastasis (%) | ||||||
 Absent | 23 (20.9) | 25 (22.7) | 0.567 | 15 (21.1) | 19 (26.8) | 0.432 |
 Present | 87 (79.1) | 85 (77.3) | 56 (78.9) | 52 (73.2) | ||
Distant metastasis (%) | ||||||
 Absent | 94 (85.5) | 106 (96.4) | 0.005** | 60 (84.5) | 69 (97.2) | 0.009** |
 Present | 16 (14.5) | 4 (3.6) | 11 (15.5) | 2 (2.8) | ||
TNM stage (%) | ||||||
 I~II | 65 (59.1) | 84 (76.4) | 0.018* | 41 (57.7) | 55 (77.5) | 0.038* |
 III~ IV | 45 (40.9) | 26 (23.6) | 30 (42.3) | 16 (22.5) | ||
 ER expression (%) | ||||||
 Negative | 57 (51.8) | 35 (32.4) | 0.004** | 46 (64.8) | 21 (30.4) | 0.000*** |
 Positive | 53 (48.2) | 73 (67.6) | 25 (35.2) | 48 (69.6) |  | |
PR expression (%) | ||||||
 Negative | 58 (52.7) | 37 (34.3) | 0.006** | 45 (63.4) | 23 (33.3) | 0.000*** |
 Positive | 52 (47.3) | 71 (65.7) | 26 (36.6) | 46 (66.7) |  | |
 HER2 expression (%) | ||||||
 Negative | 39 (35.5) | 40 (37.0) | 0.808 | 25 (35.2) | 29 (42.0) | 0.407 |
 Positive | 71 (64.5) | 68 (63.0) | 46 (64.8) | 40 (58.0) |  | |